CSF GABA levels in Parkinson's disease.
CSF levels of GABA were investigated in a group of Parkinson patients without drug treatment and a group of Parkinson patients under treatment with L-DOPA or anticholinergics. Probenecid results in an elevation of CSF GABA levels in healthy persons. The results indicate a significant decrease of GABA levels in CSF in untreated Parkinson patients. Parkinson patients treated with L-DOPA or anticholinergics show nearly normal CSF GABA levels. This may suggest that the altered GABA function in Parkinson's disease is secondary to changes in the dopamine system.
D004298:Dopamine / Q000378:metabolism; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000378:metabolism; D011339:Probenecid / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000134:cerebrospinal fluid*
D007980:Levodopa; D005680:gamma-Aminobutyric Acid; D011339:Probenecid; D004298:Dopamine